Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Donepezil delays progression to AD in MCI subjects with depressive symptoms.

Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group..

Neurology. 2009 Jun 16;72(24):2115-21. doi: 10.1212/WNL.0b013e3181aa52d3.

PMID:
19528519
2.

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.

Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.

Neurology. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. Epub 2009 Jan 28.

PMID:
19176895
3.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
4.

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ; Alzheimer's Disease Cooperative Study..

Neurology. 2007 May 8;68(19):1588-95. Epub 2007 Feb 7.

PMID:
17287448
5.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group..

N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.

PMID:
15829527
6.

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.

Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R.

BMC Geriatr. 2013 Jun 6;13:56. doi: 10.1186/1471-2318-13-56.

PMID:
23742728
7.

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.

Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S; Donepezil 401 Study Group..

Neurology. 2004 Aug 24;63(4):651-7.

PMID:
15326237
8.

Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.

van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR Jr, DeCarli C; Alzheimer's Disease Cooperative Study Group..

J Neurol. 2008 Sep;255(9):1302-8. doi: 10.1007/s00415-008-0874-y. Epub 2008 Sep 25.

PMID:
18825439
9.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
10.

Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design.

Pelton GH, Andrews H, Roose SP, Marcus SM, D'Antonio K, Husn H, Petrella JR, Zannas AS, Doraiswamy PM, Devanand DP.

Contemp Clin Trials. 2014 Mar;37(2):200-8. doi: 10.1016/j.cct.2013.11.015. Epub 2013 Dec 5.

PMID:
24315979
11.

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.

Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR.

J Am Geriatr Soc. 2003 Jul;51(7):937-44.

PMID:
12834513
12.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

PMID:
20678673
13.

Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.

Doody RS, Ferris S, Salloway S, Yijun Sun, Goldman R, Yikang Xu, Gao J, Murthy AK.

Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):155-9. doi: 10.1177/1533317509352334. Epub 2009 Nov 30.

PMID:
19949165
14.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
15.

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.

Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group..

Arch Neurol. 2001 Mar;58(3):427-33.

PMID:
11255446
16.

Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.

Kudoh C, Arita R, Honda M, Kishi T, Komatsu Y, Asou H, Mimura M.

Psychogeriatrics. 2016 Mar;16(2):85-92. doi: 10.1111/psyg.12125. Epub 2015 Apr 27.

PMID:
25918972
17.

Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.

Yatabe Y, Hashimoto M, Kaneda K, Honda K, Ogawa Y, Yuuki S, Ikeda M.

Psychogeriatrics. 2013 Jun;13(2):88-93. doi: 10.1111/psyg.12004.

PMID:
23909965
18.

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

Rogers SL, Doody RS, Mohs RC, Friedhoff LT.

Arch Intern Med. 1998 May 11;158(9):1021-31.

PMID:
9588436
19.

Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.

Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH.

Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):260-7. doi: 10.1097/WAD.0b013e31819cb760.

PMID:
19812469
20.

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.

Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ.

Neurology. 2008 Jan 15;70(3):191-9. doi: 10.1212/01.wnl.0000287091.57376.65.

PMID:
18195264

Supplemental Content

Support Center